FilingSEC EDGAR8-K
Incannex Healthcare Commences Phase 2 Dosing for OSA Candidate IHL-42X
· SEC accepted
StagePhase 2
Filing content
Incannex Healthcare has dosed the first patient in its Phase 2 dose-optimization study for IHL-42X, an oral combination drug candidate for obstructive sleep apnea.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…